1
|
Smyth MJ, Ngiow SF, Ribas A and Teng MW:
Combination cancer immunotherapies tailored to the tumour
microenvironment. Nat Rev Clin Oncol. 13:143–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Abastado JP: The next challenge in cancer
immunotherapy: Controlling T-cell traffic to the tumor. Cancer Res.
72:2159–2161. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Fridman WH, Galon J, Pagès F, Tartour E,
Sautès-Fridman C and Kroemer G: Prognostic and predictive impact of
intra- and peritumoral immune infiltrates. Cancer Res.
71:5601–5605. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Draghiciu O, Nijman HW and Daemen T: From
tumor immunosuppression to eradication: Targeting homing and
activity of immune effector cells to tumors. Clin Dev Immunol.
2011:4390532011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Klug F, Prakash H, Huber PE, Seibel T,
Bender N, Halama N, Pfirschke C, Voss RH, Timke C, Umansky L, et
al: Low-dose irradiation programs macrophage differentiation to an
iNOS+/M1 phenotype that orchestrates effective T cell
immunotherapy. Cancer Cell. 24:589–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Domanska UM, Kruizinga RC, Nagengast WB,
Timmer-Bosscha H, Huls G, de Vries EG and Walenkamp AM: A review on
CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer.
49:219–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kang TH, Mao CP, Lee SY, Chen A, Lee JH,
Kim TW, Alvarez RD, Roden RB, Pardoll D, Hung CF and Wu TC:
Chemotherapy acts as an adjuvant to convert the tumor
microenvironment into a highly permissive state for
vaccination-induced antitumor immunity. Cancer Res. 73:2493–2504.
2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Marchesi F, Grizzi F, Laghi L, Mantovani A
and Allavena P: Molecular mechanisms of pancreatic cancer
dissemination: The role of the chemokine system. Curr Pharm Des.
18:2432–2438. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Franciszkiewicz K, Boissonnas A, Boutet M,
Combadière C and Mami-Chouaib F: Role of chemokines and chemokine
receptors in shaping the effector phase of the antitumor immune
response. Cancer Res. 72:6325–6332. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Ohtani H, Jin Z, Takegawa S, Nakayama T
and Yoshie O: Abundant expression of CXCL9 (MIG) by stromal cells
that include dendritic cells and accumulation of CXCR3+ T cells in
lymphocyte-rich gastric carcinoma. J Pathol. 217:21–31. 2009.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Frangioni JV: In vivo near-infrared
fluorescence imaging. Curr Opin Chem Biol. 7:626–634. 2003.
View Article : Google Scholar : PubMed/NCBI
|
12
|
He X, Gao J, Gambhir SS and Cheng Z:
Near-infrared fluorescent nanoprobes for cancer molecular imaging:
Status and challenges. Trends Mol Med. 16:574–583. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
DU X, Wang X, Ning N, Xia S, Liu J, Liang
W, Sun H and Xu Y: Dynamic tracing of immune cells in an orthotopic
gastric carcinoma mouse model using near-infrared fluorescence live
imaging. Exp Ther Med. 4:221–225. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu G, Yao K, Wang B, Chen Y, Zhou F, Guo
Y, Xu J and Shi H: Immunotherapy of Epstein-Barr virus associated
malignancies using mycobacterial HSP70 and LMP2A356-364 epitope
fusion protein. Cell Mol Immunol. 6:423–431. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Draghiciu O, Nijman HW and Daemen T: From
tumor immunosuppression to eradication: Targeting homing and
activity of immune effector cells to tumors. Clin Dev Immunol.
2011:4390532011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Demaria S, Pilones KA, Vanpouille-Box C,
Golden EB and Formenti SC: The optimal partnership of radiation and
immunotherapy: From preclinical studies to clinical translation.
Radiat Res. 182:170–181. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Reynders K and De Ruysscher D:
Radiotherapy and immunotherapy: Improving cancer treatment through
synergy. Prog Tumor Res. 42:67–78. 2015.PubMed/NCBI
|
18
|
Kalbasi A, June CH, Haas N and Vapiwala N:
Radiation and immunotherapy: A synergistic combination. J Clin
Invest. 123:2756–2763. 2013. View
Article : Google Scholar : PubMed/NCBI
|
19
|
Soukup K and Wang X: Radiation meets
immunotherapy - a perfect match in the era of combination therapy?
Int J Radiat Biol. 91:299–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
20
|
Patel NR, Lanciano R, Sura K, Yang J,
Lamond J, Feng J, Good M, Gracely EJ, Komarnicky L and Brady L:
Stereotactic body radiotherapy for re-irradiation of lung cancer
recurrence with lower biological effective doses. J Radiat Oncol.
4:65–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Bryant J, Ahern DJ and Brennan FM: CXCR4
and vascular cell adhesion molecule 1 are key chemokine/adhesion
receptors in the migration of cytokine-activated T cells. Arthritis
Rheum. 64:2137–2146. 2012. View Article : Google Scholar : PubMed/NCBI
|
22
|
Lim JY, Gerber SA, Murphy SP and Lord EM:
Type I interferons induced by radiation therapy mediate recruitment
and effector function of CD8(+) T cells. Cancer Immunol Immunother.
63:259–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Matsumura S, Wang B, Kawashima N,
Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti
SC, Dustin ML and Demaria S: Radiation-induced CXCL16 release by
breast cancer cells attracts effector T cells. J Immunol.
181:3099–3107. 2008. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhu Q, Han X, Peng J, Qin H and Wang Y:
The role of CXC chemokines and their receptors in the progression
and treatment of tumors. J Mol Histol. 43:699–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
|